ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Psychometric properties comparison of EQ-5D-Y-3L and CHU-9D in children with adenoid hypertrophy.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis study aims to assess the psychometric properties of two preference-based instruments, EQ-5D-Y-3 L and CHU-9D, in assessing the health-related quality of life of children with adenoid hypertrophy.
methodsEQ-5D-Y-3 L and CHU-9D were completed in a random sequence by children with adenoid hypertrophy (aged 8-15years) from three hospitals in XX city. The instruments were systematically compared for distribution, ceiling effects, agreement, construct validity, known‑groups validity, and discriminative ability (via AUC, relative efficiency, orthogonal polynomial contrasts, and ANCOVA) in distinguishing disease severity levels.
resultsThis study compared the performance of the EQ-5D-Y-3 L and CHU-9D in 644 children with adenoid hypertrophy (mean age 10.63 years). The two instruments showed poor agreement (ICC = 0.691). In discriminating disease severity, the CHU-9D demonstrated superior sensitivity, with larger effect sizes (η²=0.257), and its relative efficiency suggested approximately 1.39 times greater overall discriminative ability (reference: EQ-5D-Y-3 L = 1). However, pairwise Cohen's d values were small for both instruments (range:0.108-0.163). ANCOVA confirmed these advantages persisted after adjusting for covariates.
conclusionsThe EQ-5D-Y-3L and CHU-9D were not interchangeable in children with adenoid hypertrophy. The CHU-9D showed superior discriminatory sensitivity, larger global effect sizes, and better model fit, particularly in detecting mild to moderate disease changes. Therefore, in health economic evaluations, the CHU-9D may be more suitable when the study aim is to identify early-stage or subtle health changes. In contrast, the EQ-5D-Y-3L provides a more stable model for assessing a consistent linear relationship between disease severity and health utility. Researchers should select the instrument based on clearly defined study objectives, while acknowledging that the observed pairwise effect sizes were modest and warrant further validation.
Indexed as
Identifiers
42518097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.